# Clinical Trials Data KIT - Document 73

# The Oncopanel Pilot (TOP) Study

## Clinical Trial: https://clinicaltrials.gov/study/NCT02171286

"eligibilityCriteria": "Patients with archival tumor tissue and a known history of invasive malignancies are eligible if they meet one or more of the following criteria:\n\n\* Advanced colorectal cancer and eligible for standard KRAS testing,\n\* Advanced non-small cell lung cancer and eligible for standard EGFR testing,\n\* Advanced melanoma and eligible for standard BRAF testing,\n\* Gastrointestinal stromal tumors (GISTs) eligible for standard c-KIT and PDGFRA testing,\n\* Being considered for potential eligibility in clinical trial.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Patients with advanced colorectal cancer, non-small cell lung cancer and melanoma and candidates for clinical trials.",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Yes, a patient with a KIT gene mutation would likely be eligible. The criteria specifically include patients with "Gastrointestinal stromal tumors (GISTs) eligible for standard c-KIT and PDGFRA testing". Since KIT mutations are part of the standard testing for GISTs, having the mutation itself doesn't exclude the patient. In fact, it's the very reason such testing is done.